Jan 2, 2018 Syros Announces Clinical Supply Agreement with Janssen to Evaluate SY-1425, Its First-in-Class Selective RARĪ± Agonist, in Combination with Daratumumab in Genomically Defined AML and MDS Patients
Dec 10, 2017 Syros Announces New Preclinical Data on SY-1365, Its First-in-Class Selective CDK7 Inhibitor, Pointing to a Potential Biomarker of Response and Combination Approach
Dec 10, 2017 Syros Announces Initial Clinical Data from Ongoing Phase 2 Trial of SY-1425 Showing Biological and Clinical Activity as Single Agent in Genomically Defined AML and MDS Patients
Dec 7, 2017 Syros Presents New Preclinical Data on SY-1365, Its First-in-Class Selective CDK7 Inhibitor, and Discovery of Potential New Drug Targets in Triple Negative Breast Cancer at San Antonio Breast Cancer Symposium
Nov 13, 2017 Syros to Present New Preclinical Data on SY-1365 and on Identification of Potential Drug Targets in Triple Negative Breast Cancer at San Antonio Breast Cancer Symposium
Nov 8, 2017 Syros Reports Third Quarter 2017 Financial Results and Highlights Accomplishments and Upcoming Milestones
Nov 1, 2017 Syros to Present Initial Clinical Data from Ongoing Phase 2 Clinical Trial of SY-1425 and New Preclinical Data on SY-1365 at ASH Annual Meeting
